Who is sponsoring NCT00244608?

NCT00244608 is sponsored by AstraZeneca.

What drugs are being tested in NCT00244608?

Interventions: Budesonide/Formoterol Turbuhaler, Budesonide Turbuhaler (Pulmicort), Terbutaline Turbuhaler.

What is the status of NCT00244608?

NCT00244608 is currently COMPLETED.

Last reviewed 2011-01-21 · How we verify

A Comparison of the Inflammatory Control of Asthma Provided by One Inhalation of Symbicort® Turbuhaler® 160/4.5 µg/Inhalation b.i.d. Plus As-needed Versus One Inhalation of Symbicort® Turbuhaler® 320/9 µg/Inhalation b.i.d. + One Inhalation of Pulmicort® Turbuhaler® 400 µg/Dose b.i.d. Plus Terbutaline Turbuhaler® 0.4 mg/Inhalation As-needed. A 12-month, Randomised, Double-blind, Parallel-group, Active Controlled, Multinational, Phase IIIB Study in Adult Patients With Asthma, EOS

NCT00244608 Phase 3 COMPLETED

The purpose of this study is to determine if a flexible dose of Symbicort has a similar effect on the airways of patients with asthma as a higher fixed-dose of Symbicort with additional glucocorticosteroids added.

Details

Lead sponsor	AstraZeneca
Phase	Phase 3
Status	COMPLETED
Enrolment	100
Start date	2005-05
Completion	2007-03

Conditions

Asthma

Interventions

Budesonide/Formoterol Turbuhaler
Budesonide Turbuhaler (Pulmicort)
Terbutaline Turbuhaler

Primary outcomes

Change in eosinophils in bronchial biopsies (first and last visit) and in sputum (5 times during the 12-month treatment period)

Countries

Denmark, France, Germany, Spain, Sweden, United Kingdom